Atara Biotherapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Atara Biotherapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.77M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $128.94M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $8.57M | Mar 7, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.69M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($85.40M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($276.13M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($228.30M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($340.14M) | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | ($306.62M) | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | ($290.98M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($230.70M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($119.49M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($79.05M) | Feb 26, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.86M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($83.44M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($276.01M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($280.51M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($340.46M) | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | ($309.05M) | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | ($295.68M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($237.11M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($121.53M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($81.24M) | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $151.48M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $224.79M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $272.53M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $282.00M | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | $244.65M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $216.10M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $167.46M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $81.21M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $56.51M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.94M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($68.72M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($192.98M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($270.43M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($220.52M) | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | ($180.76M) | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | ($235.63M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($179.77M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($87.50M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($60.03M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $246.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.22M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $4.19M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $10.58M | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | $4.51M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $5.73M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $35.93M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $20.23M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $3.02M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.24M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $109.10M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $165.50M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $376.42M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $468.13M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $588.12M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $342.94M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $391.84M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $217.78M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $263.91M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.74M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $206.38M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $264.74M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $249.78M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $188.51M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $125.78M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $52.16M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $52.98M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $39.92M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $10.18M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.50M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($97.28M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $99.23M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $126.64M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $279.61M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $462.34M | Feb 8, 2023 |
| FY2022 | Dec 31, 2019 | $290.78M | Feb 8, 2023 |
| FY2021 | Dec 31, 2018 | $339.22M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $177.86M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $253.74M | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.02B) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($2.05B) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.97B) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($1.69B) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.46B) | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | ($1.12B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($817.96M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($527.35M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($296.65M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($177.16M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.48M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $25.03M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $25.84M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $92.94M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $106.08M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $200.40M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $74.32M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $60.70M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $79.22M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $47.97M | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (65) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | (4) | Feb 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (65) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | (4) | Feb 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.32M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 5.86M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 4.26M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 95.93M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 91.67M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | 83.37M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 56.81M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 45.95M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 30.73M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 28.93M | Feb 27, 2018 |